» Articles » PMID: 39748955

Using Multiple Drug Similarity Networks to Promote Adverse Drug Event Detection

Overview
Journal Heliyon
Specialty Social Sciences
Date 2025 Jan 3
PMID 39748955
Authors
Affiliations
Soon will be listed here.
Abstract

The occurrence of an adverse drug event (ADE) has become a serious social concern of public health. Early detection of ADEs can lower the risk of drug safety as well as the expense of the drug. While post-market spontaneous reports of ADEs remain a cornerstone of pharmacovigilance, most existing signal detection algorithms rely on substantial accumulated data, limiting their applicability to early ADE detection when reports are scarce. To address this issue, we propose a label propagation model for generating enhanced drug safety signals using multiple drug features. We first construct multiple drug similarity networks using a range of drug features. We then calculate initial drug safety signals using conventional signal detection algorithms. These original signals are subsequently propagated across each drug similarity network to obtain enhanced drug safety signals. We evaluate our proposed model using two common signal detection algorithms on data from the FDA Adverse Event Reporting System (FAERS). Results demonstrate that enhanced drug safety signals with pre-clinical information outperform the standard safety signal detection algorithms on early ADE detection. In addition, we systematically evaluate the performance of different drug similarities against different types of ADEs. Furthermore, we have developed a web interface (http://drug-drug-sim.aimedlab.net/) to display our multiple drug similarity scores, facilitating access to this valuable resource for drug safety monitoring.

References
1.
Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah N . Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther. 2013; 93(6):539-46. PMC: 3857139. DOI: 10.1038/clpt.2013.24. View

2.
Liu R, Zhang P . Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports. BMC Med Inform Decis Mak. 2019; 19(1):279. PMC: 6918608. DOI: 10.1186/s12911-019-0999-1. View

3.
Rosen A, Case E, Dusza S, Balagula Y, Gordon J, West D . Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic. Am J Clin Dermatol. 2013; 14(4):327-33. DOI: 10.1007/s40257-013-0021-0. View

4.
Giacomini K, Krauss R, Roden D, Eichelbaum M, Hayden M, Nakamura Y . When good drugs go bad. Nature. 2007; 446(7139):975-7. DOI: 10.1038/446975a. View

5.
Xiao C, Li Y, Baytas I, Zhou J, Wang F . An MCEM Framework for Drug Safety Signal Detection and Combination from Heterogeneous Real World Evidence. Sci Rep. 2018; 8(1):1806. PMC: 5789130. DOI: 10.1038/s41598-018-19979-7. View